振东制药：中药1.1类新药星蒌承气颗粒IIa期临床试验首例受试者入组

Core Viewpoint - The company, Zhendong Pharmaceutical, has announced that its research and development of the traditional Chinese medicine Class 1 new drug, Xinglou Chengqi Granules, is currently undergoing Phase IIa clinical trials, with the first subject successfully enrolled and administered recently [1] Group 1: Drug Development - The drug is indicated for phlegm clearance and is intended for use in the acute phase of ischemic stroke with phlegm-heat obstructing the channels, presenting symptoms such as hemiplegia, unilateral numbness, speech difficulties, dizziness, and constipation [1] - The clinical trial aims to evaluate the efficacy and safety of Xinglou Chengqi Granules in treating the specified conditions associated with ischemic stroke [1]